• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Hamlet BioPharma

7.11 SEK

-0.56 %

Less than 1K followers

HAMLET B

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.56 %
-2.34 %
-0.14 %
+20.51 %
+34.15 %
+87.35 %
+167.73 %
-0.02 %
+221.36 %

Hamlet BioPharma operates in the pharmaceutical industry. The company conducts drug development based on a tumor-killing protein-lipid complex, formed from two natural and harmless molecules found in breast milk. The development aims to produce preparations that will primarily be used for the treatment and prevention of cancer diseases. Hamlet BioPharma was founded in 2015 and is headquartered in Lund.

Read more
Market cap
1.32B SEK
Turnover
490.02K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
ShowingAll content types

Financial calendar
28.8
2026

Annual report '26

13.11
2026

Interim report Q1'27

20.11
2026

General meeting '26

Press release16 hours ago

Hamlet BioPharma AB (publ): Pre-initiation visit in Prague, for the Phase III trial of Alpha1H in bladder cancer

Hamlet BioPharma
Press release6/10/2026, 12:30 PM

Hamlet BioPharma AB (publ): Continued success for the new anti-infective therapies developed by Hamlet BioPharma

Hamlet BioPharma
Regulatory press release5/22/2026, 7:00 AM

Hamlet BioPharma AB (publ): Q3 INTERIMREPORTJANUARY-MARCH 2026

Hamlet BioPharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release5/21/2026, 9:15 AM

Hamlet BioPharma AB (publ): Monthly investor meeting on the 22nd of May when Hamlet BioPharma is releasing it's Q3 report

Hamlet BioPharma
Press release5/18/2026, 1:15 PM

Hamlet BioPharma AB (publ): Hamlet Biopharma Secures New Patents and Allowances, Going from Strength to Strength in Innovation and Technology

Hamlet BioPharma
Press release4/23/2026, 1:15 PM

Hamlet BioPharma AB (publ): Monthly investor meeting on the 29th of April

Hamlet BioPharma
Press release3/30/2026, 8:00 AM

Hamlet BioPharma AB (publ): Hamlet BioPharma presented at the Financial Stockholm event on March 26, 2026

Hamlet BioPharma
Press release3/17/2026, 9:00 AM

Hamlet BioPharma AB (publ): Hamlet BioPharmas digital monthly investor meeting on the 18th of March

Hamlet BioPharma
Regulatory press release3/6/2026, 5:31 PM

Hamlet BioPharma AB (publ): Hamlet BioPharma signed a Letter of Intent to outline terms of a potential collaboration and a commercial agreement concerning Alpha 1H.

Hamlet BioPharma
Regulatory press release2/13/2026, 8:00 AM

Hamlet BioPharma AB (publ): Q2 INTERIM REPORT OCT - DEC 2025

Hamlet BioPharma
Press release2/12/2026, 4:03 PM

Hamlet BioPharma AB (publ): Nature Microbiology publishes the paper `'Targeted innate immune inhibition therapy compared with antibiotics for recurrent acute cystitis: a randomized, open-label phase 2 trial.''

Hamlet BioPharma
Press release2/11/2026, 9:30 AM

Hamlet BioPharma AB (publ): Monthly investor meeting on the 13th of February when Hamlet BioPharma is releasing it's Q2 report

Hamlet BioPharma
Press release2/3/2026, 9:15 AM

Hamlet BioPharma AB (publ): Collaboration agreement between Hamlet BioPharma and Immunoforge in South Korea

Hamlet BioPharma
Press release1/27/2026, 11:00 AM

Hamlet BioPharma AB (publ): 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗼𝗻 𝗡𝗼𝘃𝗲𝗹 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗖𝗮𝗻𝗰𝗲𝗿

Hamlet BioPharma
Press release1/16/2026, 1:00 PM

Hamlet BioPharma AB (publ): Invitation to digital meeting focusing on novel strategies for treating bacterial infections without antibiotics

Hamlet BioPharma
Press release12/18/2025, 1:30 PM

Hamlet BioPharma AB (publ): The HAMLET project featured in Cancerfonden's Christmas Campaign

Hamlet BioPharma
Press release11/19/2025, 7:20 AM

BioStock: Video from Hamlet Biopharma's presentation at BioStock Life Science Summit 202

Hamlet BioPharma
Regulatory press release11/14/2025, 8:00 AM

Hamlet BioPharma AB (publ): Q1 INTERIM REPORT JULY - SEPT 2025

Hamlet BioPharma
Regulatory press release11/10/2025, 8:00 AM

Hamlet BioPharma AB (publ): Hamlet BioPharma Receives FDA Pivotal-Study Feedback for Novel Neoadjuvant Therapy in Non-Muscle Invasive Bladder Cancer

Hamlet BioPharma
Press release11/5/2025, 1:00 PM

Hamlet BioPharma AB (publ): Clinical study in infants with febrile kidney infection supports Hamlet BioPharma's strategy for non-antibiotic treatment of bacterial infections

Hamlet BioPharma